|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ampullary cancer of intestinal origin and duodenal cancer-A logical clinical and therapeutic subgroup in periampullary cancer显示文摘Periampullary cancers include pancreatic, ampullary, biliary and duodenal cancers. At presentation, the majority of periampullary tumours have grown to involve the pancreas, bile duct, ampulla and duodenum. This can result in difficulty in defining the primary site of origin in all but the smallest tumors due to anatomical proximity and architectural distortion. This has led to variation in the reported proportions of resected periampullary cancers. Pancreatic cancer is the most common cancer resected with a pancreaticoduodenectomy followed by ampullary(16%-50%), bile duct(5%-39%), and duodenal cancer(3%-17%). Patients with resected duodenal and ampullary cancers have a better reported median survival(29-47 mo and 22-54 mo) compared to pancreatic cancer(13-19 mo). The poorer survival with pancreatic cancer relates to differences in tumour characteristics such as a higher incidence of nodal, neural and vascular invasion. While small ampullary cancers can present early with biliary obstruction, pancreatic cancers need to reach a certain size before biliary obstruction ensues. This larger size at presentation contributes to a higher incidence of resection margin involvement in pancreatic cancer. Ampullary cancers can be subdivided into intestinal or pancreatobiliary subtype cancers with histomolecular staining. This avoids relying on histomorphology alone, as even some poorly differentiated cancers preserve the histomolecular profile of their mucosa of origin. Histomolecular profiling is superior to anatomic location in prognosticating survival. Ampullary cancers of intestinal subtype and duodenal cancers are similar in their intestinal origin and form a logical clinical and therapeutic subgroup of periampullary cancers. They respond to 5-FU based chemotherapeutic regimens such as capecitabine-oxaliplatin. Unlike pancreatic cancers, KRAS mutation occurs in only approximately a third of ampullary and duodenal cancers. Future clinical trials should group ampullary cancers of intestinal origin and duodenal cancers together given their similarities and their response to fluoropyrimidine therapy in combination with oxaliplatin. The addition of anti-epidermal growth factor receptor therapy in this group warrants study. | Manju D Chandrasegaram Anthony J Gill Jas Samra Tim Price John Chen Jonathan Fawcett Neil D Merrett | 2017 | World Journal of Gastrointestinal Oncology2017，9，10： | 4 |
| 2 | The effect of Mn on the microstructure and properties of BaSrTiO 3 with B 2 O 3 –Li 2 CO 3显示文摘 | Tao Hu Tim J. Price David M. Iddles Antti Uusim?ki Heli Jantunen | 2005 | Journal of the European Ceramic Society2005，，12： | 1 |
| 3 | Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Histopathologic Correlation in the Initial Staging of Head and Neck Cancer显示文摘 | Anthony Hannah Andrew M. Scott Henri Tochon-Danguy J. Gordon Chan Tim Akhurst Salvatore Berlangieri David Price Gerard J. Smith Tony Schelleman W. J. McKay Andrew Sizeland | 2002 | Annals of Surgery2002，，： | 1 |
| 4 | Technology Forecasting of CCD and CMOS= Digital Imaging Technology using TRIZ显示文摘 | MICHAEL TOMPKINS TIM PRICE CLAPP TIMOTHY | 2006 | The TRIZ Journal2006，，： | 1 |
| 5 | A Mobile App to Replace the Goniometer? A Pilot Study Focusing on the Measurement of Knee Range of Movement显示文摘Background: The universal goniometer is commonly used to measure knee range of movement in clinical practice. However, research has demonstrated that the universal goniometer lacks reliability failing to meet the standard of clinically acceptable error (5°). Objective: This study tested the concurrent validity and intra-rater reliability of a photographic based “app” developed for feedback in sport, the Hudl Ubersense App, as an alternative instrument for measuring knee range of movement. Methods: Measurements of knee range of movement were made concurrently with the electrogoniometer (the gold standard) and the Hudl Ubersense App across a pre-determined randomised set of 20 functional knee angles between 35° and 130°. This was then repeated. The pre-agreed standard of concurrent validity was that 95% of Hudl Ubersense App measurements would be within 5° of the electrogoniometer and differences were displayed in Bland-Altman plots. Results: Thirty nine (97%) of the forty app readings differed from the corresponding electrogoniometer readings by less than 5°. The mean differences between the electrogoniometer and Hudl Ubersense App measurements over each trial were 1.75° and 0.80° respectively, indicating a high level of concurrent validity. There was less than 1.0° mean difference between the first and second set of results indicating a high level of intra-rater reliability. Conclusions: The results suggest that the Hudl Ubersense App has high levels of concurrent validity (using the electrogoniometer as the gold standard) and intra-rater reliability, scoring better than previous research on the current clinical measuring device, the universal goniometer. The Hudl Ubersense App has clinical advantages over the electrogoniometer, so further research is recommended to determine its inter-rater reliability, acceptability, and appropriate clinical practice procedures. | Sara Aspinall Tim Sparks Andrew King Mike Price Steven Godsiff | 2019 | Journal of Sports Science2019，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员